MYOF and breast carcinoma: The identification of myoferlin as a key regulator of EGFR (Epidermal Growth Factor Receptor) activity through inhibition of non-clathrin endocytosis in breast cancer cells was important in understanding the molecular mechanisms involved in cancer growth (Turtoi et al., 2013).